Axsome Therapeutics
Axome Therapeutics is a New York-based biopharmaceutical company developing therapies for central nervous system disorders.
All edits by Konstantin Glushkov
AXS-05 for alzheimer’s disease agitation, major depressive disorder, smoking cessation;
AXS-07 for migraine;
AXS-12 for narcolepsy: orphan drug designation;
AXS-14 for fibromyalgia.
- AXS-05 for alzheimer’s disease agitation, major depressive disorder, smoking cessation. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD).
- AXS-07 for migraine. AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan.
- AXS-12 for narcolepsy: orphan drug designation. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy.
- AXS-14 for fibromyalgia. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.
Axsome has garnered Breakthrough Therapy Status from the FDA for three indications.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing therapies for central nervous system (CNS) disorders. The company is public, based in New York, USA, founded in 2012. Nasdaq ticker is AXSM.
Clinical trials:
AXS-05 for alzheimer’s disease agitation, major depressive disorder, smoking cessation;
AXS-07 for migraine;
AXS-12 for narcolepsy: orphan drug designation;
AXS-14 for fibromyalgia.
Find more companies like Axsome Therapeutics
